FITC-Labeled Human VEGF165 Protein, His Tag

VEGF165 is the most abundant splice variant of VEGF-A. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 that function to enhance VEGFR2 signaling. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin. VEGF plays a key role in tumor angiogenesis in many cancers.

Product Specifications

Background

Specifications

This protein carries a polyhistidine tag at the N-terminus. The protein has a calculated MW of 21.1 kDa. The protein migrates as 27-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

P15692-4

Expression Region

Ala 27 - Arg 191

Host

HEK293

Target

VEGF165

Conjugation

FITC Labeled

Tag

N-10xHis

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Bevacizumab at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human VEGF165, His Tag (Cat. No. VE5-HF248) with a linear range of 39-156 ng/mL (QC tested).